Plain-English translation of NCT07351669 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial compares two types of CT scanning — a newer advanced scan called spectral CT and a standard CT scan — to see which one better shows whether your liver cancer treatment has worked. You would have already received chemoembolization (a procedure that delivers cancer-fighting medicine directly to the tumor), and this study asks whether the newer scanning method can more accurately tell if that treatment succeeded.
After liver cancer treatment, doctors need clear pictures to know whether the tumor shrank or disappeared. A newer scanning technology may provide better information than standard scans, which could help doctors decide on next steps more confidently.
You likely qualify if…
You likely don't qualify if…
You would return to the hospital 4 to 8 weeks after your chemoembolization treatment for an advanced CT scan with contrast dye. Within one week, you would also need to have either surgical evaluation, a special imaging procedure called DSA, or an MRI scan so researchers can confirm the accuracy of the CT results. The study involves these imaging appointments only — no medications or lifestyle changes are required.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China
Sponsor
Zhongda Hospital
Enrollment target
~121 participants
Started
January 2026
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shuhang Zhang
Zhongda Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.